ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3079

Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD)

Christopher P. Denton1, J. Gerry Coghlan2, Hossein-Ardeschir Ghofrani3, Friedrich Grimminger3, Jianguo He4, Gabriela Riemekasten5, Dario Vizza6, Annette Boeckenhoff7, Christian Meier8, Janethe de Oliveira Pena9 and Marc Humbert10, 1Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, 2Royal Free London NHS Foundation Trust, London, England, 3University of Giessen and Marburg Lung Center, Giessen, Germany, 4Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Clinic of Rheumatology and Clinical Immunology, Berlin, Germany, 6La Sapienza University of Rome, Rome, Italy, 7Bayer Pharma AG, Wuppertal, Germany, 8Bayer Pharma AG, Berlin, Germany, 9Bayer HealthCare Pharma, Whippany, NJ, 10Université Paris-Sud, Laboratoire d’Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin–Bicêtre, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, clinical trials, connective tissue diseases and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: ACR Plenary Session III: Discovery 2015

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

PAH associated with CTD (PAH-CTD) has a worse prognosis than idiopathic/familial PAH. Here we report a prospective subgroup analysis of patients with PAH-CTD from the PATENT studies of the soluble guanylate cyclase stimulator, riociguat.

Methods:

PATENT-1 was a 12-week, randomized Phase III trial in which patients with PAH received either riociguat individually dose-adjusted up to 2.5 mg tid (2.5 mg–maximum group), riociguat up to 1.5 mg tid (1.5 mg–maximum group; exploratory), or placebo. The primary endpoint was change from baseline in 6-minute walking distance (6MWD). Long-term safety and survival were assessed during the PATENT-2 open-label extension.

Results:

In PATENT-1, 111 patients had PAH-CTD (systemic sclerosis [SSc; n=66, including diffuse SSc and limited SSc], non-SSc CTD [n=39], and unspecified CTD [n=6], derived post-hoc from the medical history using MedDRA preferred terms). Seventy PAH-CTD patients were pretreated with PAH-specific therapy, of whom 59 were receiving endothelin receptor antagonists. Of the overall group of PAH-CTD patients, 71, 15, and 25 were randomized to riociguat 2.5 mg–maximum, riociguat 1.5 mg–maximum, and placebo, respectively. At baseline, mean±SD 6MWD was 348±70 m in the riociguat 2.5 mg–maximum group and 361±88 m in the placebo group. At Week 12, there was an improvement in 6MWD in the 2.5 mg–maximum riociguat group (+18 m) and a deterioration in the placebo group (–8 m) (Figure 1; PAH-CTD population; intention-to-treat, imputed values). Consistent with other studies, the least-squares mean treatment difference between riociguat and placebo (+28 m) in patients with PAH-CTD was lower than that observed in the overall study population (+36 m). In the SSc subgroup the placebo-corrected mean treatment difference in change from baseline was mostly based on the deterioration in exercise capacity on placebo (Figure 1). At the March 2014 cut-off for PATENT-2, 70 patients with PAH-CTD had been receiving treatment for ≥2 years. In PATENT-2, efficacy in 6MWD was maintained over 2 years in patients with PAH-CTD receiving riociguat. Clinical worsening events were experienced by <30% of patients with PAH-CTD in the PATENT-2 study, with a higher rate of events occurring in the SSc subcategory, which was driven by patients needing to start new PAH-specific treatments. At 2 years, similar survival rates (95% CI) were observed for patients with PAH-CTD, SSc, idiopathic/familial PAH and the overall population: 93% (85–97%), 94% (82–98%), 93% (89–96%), and 93% (90–95%), respectively. Riociguat had a similar safety profile in patients with PAH-CTD as observed in the overall population.

Conclusion:

In patients with PAH-CTD, riociguat was associated with long-term improvements in exercise capacity. The 2‑year survival rates in riociguat-treated patients with PAH-CTD were high and similar to patients with idiopathic/familial PAH.


Disclosure: C. P. Denton, GlaxoSmithKline, 2,Actelion Pharmaceuticals US, 5,GlaxoSmithKline, 5,Serono, 5,Inventiva, 5,CSL Behring, 2,Bayer, 5; J. G. Coghlan, None; H. A. Ghofrani, Novartis, Pfizer, 5,Novartis, Pfizer, 8; F. Grimminger, None; J. He, None; G. Riemekasten, None; D. Vizza, Bayer Pharma AG, Actelion, GSK, Utel, 5,Actelion, Novartis, GSK, Bayer Pharma AG, Gilead, 2,Bayer Pharma AG, Actelion, GSK, Utel, 8; A. Boeckenhoff, Bayer Pharma AG, 3; C. Meier, Bayer Pharma AG, 3; J. de Oliveira Pena, Bayer HealthCare Pharmaceuticals Inc., 3; M. Humbert, Actelion, Bayer, GSK, Novartis, Pfizer, 5,Actelion, Bayer, GSK, Novartis, Pfizer, 8.

To cite this abstract in AMA style:

Denton CP, Coghlan JG, Ghofrani HA, Grimminger F, He J, Riemekasten G, Vizza D, Boeckenhoff A, Meier C, de Oliveira Pena J, Humbert M. Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-riociguat-in-patients-with-pulmonary-arterial-hypertension-pah-associated-with-connective-tissue-disease-ctd/. Accessed January 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-riociguat-in-patients-with-pulmonary-arterial-hypertension-pah-associated-with-connective-tissue-disease-ctd/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.